Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-14

Clinical Trial Update: Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer [NA]

View source ↗

Summary

GT307 is an autologous tumor-infiltrating lymphocyte therapy being studied for advanced colorectal cancer. The trial is currently recruiting under sponsor Grit …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GT307 (Autologous tumor-infiltrating lymphocytes (GT307))

Snippet

Sponsor: Grit Biotechnology | Conditions: Adult | NA | Status: RECRUITING